{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:29:34Z","timestamp":1789972174608,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC 100-2314-B-182A-092-MY3"],"award-info":[{"award-number":["NSC 100-2314-B-182A-092-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC 102-2221-E- 007-021-MY2"],"award-info":[{"award-number":["NSC 102-2221-E- 007-021-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC 102-2314-B-182-049-MY3"],"award-info":[{"award-number":["NSC 102-2314-B-182-049-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC 103-2623-E-182-001-NU"],"award-info":[{"award-number":["NSC 103-2623-E-182-001-NU"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3A0513"],"award-info":[{"award-number":["CMRPG3A0513"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG391514"],"award-info":[{"award-number":["CMRPG391514"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12149-017-1174-3","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T04:11:06Z","timestamp":1493266266000},"page":"506-513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["[18F]FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease"],"prefix":"10.1007","volume":"31","author":[{"given":"Chi-Chang","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siao-Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing-Tsung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ping","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7222-2601","authenticated-orcid":false,"given":"Shiaw-Pyng","family":"Wey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Han","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"1174_CR1","doi-asserted-by":"crossref","first-page":"a008870","DOI":"10.1101\/cshperspect.a008870","volume":"2","author":"J Massano","year":"2012","unstructured":"Massano J, Bhatia KP. Clinical approach to Parkinson\u2019s disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012;2:a008870.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1174_CR2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1749-6632.1988.tb32998.x","volume":"515","author":"WC Miller","year":"1988","unstructured":"Miller WC, DeLong MR. Parkinsonian symptomatology. An anatomical and physiological analysis. Ann N Y Acad Sci. 1988;515:287\u2013302.","journal-title":"Ann N Y Acad Sci"},{"key":"1174_CR3","first-page":"15","volume":"46","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson\u2019s disease. J Neural Transm Suppl. 1995;46:15\u201331.","journal-title":"J Neural Transm Suppl"},{"key":"1174_CR4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","volume":"28","author":"DJ Moore","year":"2005","unstructured":"Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson\u2019s disease. Annu Rev Neurosci. 2005;28:57\u201387.","journal-title":"Annu Rev Neurosci"},{"key":"1174_CR5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.jcbfm.9600276","volume":"26","author":"NI Bohnen","year":"2006","unstructured":"Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1198\u2013212.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1174_CR6","first-page":"237","volume":"86","author":"KA Frey","year":"2001","unstructured":"Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol. 2001;86:237\u201347.","journal-title":"Adv Neurol"},{"key":"1174_CR7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0969-8051(96)00023-6","volume":"23","author":"MR Kilbourn","year":"1996","unstructured":"Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol. 1996;23:467\u201371.","journal-title":"Nucl Med Biol"},{"key":"1174_CR8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.nucmedbio.2006.05.006","volume":"33","author":"R Goswami","year":"2006","unstructured":"Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33:685\u201394.","journal-title":"Nucl Med Biol"},{"key":"1174_CR9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.108.051680","volume":"49","author":"MP Kung","year":"2008","unstructured":"Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, Blankemeyer E, et al. In vivo imaging of \u03b2-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 2008;49:1171\u20136.","journal-title":"J Nucl Med"},{"key":"1174_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.nucmedbio.2006.12.005","volume":"34","author":"MP Kung","year":"2007","unstructured":"Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol. 2007;34:239\u201346.","journal-title":"Nucl Med Biol"},{"key":"1174_CR11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","volume":"5","author":"U Ungerstedt","year":"1968","unstructured":"Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. 1968;5:107\u201310.","journal-title":"Eur J Pharmacol"},{"key":"1174_CR12","first-page":"310","volume":"309","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard PA Jr. Parkinson\u2019s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med. 1983;309:310.","journal-title":"N Engl J Med"},{"key":"1174_CR13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.molbrainres.2005.01.012","volume":"134","author":"M Shimoji","year":"2005","unstructured":"Shimoji M, Zhang L, Mandir AS, Dawson VL, Dawson TM. Absence of inclusion body formation in the MPTP mouse model of Parkinson\u2019s disease. Brain Res Mol Brain Res. 2005;134:103\u20138.","journal-title":"Brain Res Mol Brain Res"},{"key":"1174_CR14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P. Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357\u201391.","journal-title":"Br J Pharmacol"},{"key":"1174_CR15","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1174_CR16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0304-3940(02)00296-3","volume":"326","author":"KS McNaught","year":"2002","unstructured":"McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson\u2019s disease. Neurosci Lett. 2002;326:155\u20138.","journal-title":"Neurosci Lett"},{"key":"1174_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-11-1","volume":"11","author":"AC Vernon","year":"2010","unstructured":"Vernon AC, Johansson SM, Modo MM. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson\u2019s disease. BMC Neurosci. 2010;11:1.","journal-title":"BMC Neurosci"},{"key":"1174_CR18","doi-asserted-by":"crossref","first-page":"e17269","DOI":"10.1371\/journal.pone.0017269","volume":"6","author":"AC Vernon","year":"2011","unstructured":"Vernon AC, Crum WR, Johansson SM, Modo M. Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson\u2019s disease. PLoS One. 2011;6:e17269.","journal-title":"PLoS One"},{"key":"1174_CR19","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","volume":"23","author":"F Fornai","year":"2003","unstructured":"Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci. 2003;23:8955\u201366.","journal-title":"J Neurosci"},{"key":"1174_CR20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2005.01.024","volume":"380","author":"H Miwa","year":"2005","unstructured":"Miwa H, Kubo T, Suzuki A, Nishi K, Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci Lett. 2005;380:93\u20138.","journal-title":"Neurosci Lett"},{"key":"1174_CR21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ana.20186","volume":"56","author":"KS McNaught","year":"2004","unstructured":"McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson\u2019s disease. Ann Neurol. 2004;56:149\u201362.","journal-title":"Ann Neurol"},{"key":"1174_CR22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ana.20936","volume":"60","author":"KS McNaught","year":"2006","unstructured":"McNaught KS, Olanow CW. Proteasome inhibitor\u2013induced model of Parkinson\u2019s disease. Ann Neurol. 2006;60:243\u20137.","journal-title":"Ann Neurol"},{"key":"1174_CR23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ana.20937","volume":"60","author":"J Bov\u00e9","year":"2006","unstructured":"Bov\u00e9 J, Zhou C, Jackson-Lewis V, Taylor J, Chu Y, Rideout HJ, et al. Proteasome inhibition and Parkinson\u2019s disease modeling. Ann Neurol. 2006;60:260\u20134.","journal-title":"Ann Neurol"},{"key":"1174_CR24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.20938","volume":"60","author":"AB Manning-Bo\u011f","year":"2006","unstructured":"Manning-Bo\u011f AB, Reaney SH, Chou VP, Johnston LC, McCormack AL, Johnston J, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol. 2006;60:256\u201360.","journal-title":"Ann Neurol"},{"key":"1174_CR25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ana.20935","volume":"60","author":"JH Kordower","year":"2006","unstructured":"Kordower JH, Kanaan NM, Chu Y, Suresh Babu R, Stansell J, Terpstra BT, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson\u2019s disease in rats and monkeys. Ann Neurol. 2006;60:264\u20138.","journal-title":"Ann Neurol"},{"key":"1174_CR26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainres.2007.06.076","volume":"1168","author":"BN Mathur","year":"2007","unstructured":"Mathur BN, Neely MD, Dyllick-Brenzinger M, Tandon A, Deutch AY. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 2007;1168:83\u20139.","journal-title":"Brain Res"},{"key":"1174_CR27","volume-title":"The rat brain in stereotaxic coordinates\u2014the new coronal set","author":"G Paxinos","year":"2004","unstructured":"Paxinos G. The rat brain in stereotaxic coordinates\u2014the new coronal set. 5th ed. Cambridge: Elsevier Academic Press; 2004.","edition":"5"},{"key":"1174_CR28","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2967\/jnumed.110.078196","volume":"51","author":"KJ Lin","year":"2010","unstructured":"Lin KJ, Weng YH, Wey SP, Hsiao T, Lu CS, Skovronsky D, et al. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med. 2010;51:1480\u20135.","journal-title":"J Nucl Med"},{"issue":"2","key":"1174_CR29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2967\/jnumed.109.070094","volume":"51","author":"N Okamura","year":"2010","unstructured":"Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O\u2019Keefe G, Jones G, Kung HF. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with 18F-AV-133. J Nucl Med. 2010;51(2):223\u20138.","journal-title":"J Nucl Med"},{"issue":"6","key":"1174_CR30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2014.290","volume":"71","author":"T Hsiao","year":"2014","unstructured":"Hsiao T, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA neurology. 2014;71(6):758\u201366.","journal-title":"JAMA neurology."},{"key":"1174_CR31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/157015906775203039","volume":"4","author":"P Bonsi","year":"2006","unstructured":"Bonsi P, Cuomo D, Martella G, Sciamanna G, Tolu M, Calabresi P, et al. Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies. Curr Neuropharmacol. 2006;4:69\u201375.","journal-title":"Curr Neuropharmacol"},{"key":"1174_CR32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuint.2011.03.013","volume":"58","author":"E Lorenc-Koci","year":"2011","unstructured":"Lorenc-Koci E, Lenda T, Antkiewicz-Michaluk L, Wardas J, Domin H, \u015amia\u0142owska M, et al. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson\u2019s disease in rats. Neurochem Int. 2011;58:839\u201349.","journal-title":"Neurochem Int"},{"key":"1174_CR33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.expneurol.2013.03.021","volume":"247","author":"S Mackey","year":"2013","unstructured":"Mackey S, Jing Y, Flores J, Dinelle K, Doudet DJ. Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry. Exp Neurol. 2013;247:19\u201324.","journal-title":"Exp Neurol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-017-1174-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-017-1174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-017-1174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T23:49:37Z","timestamp":1569109777000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-017-1174-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s12149-017-1174-3","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]}}}